Clinical trials · New York, NY
Non-squamous Non-small Cell Lung Cancer clinical trials in New York
We’re tracking 43 recruiting non-squamous non-small cell lung cancer studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
Fresh Meadows, New YorkAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
The Bronx, New YorkAges 18 years+ - NCT07227298RecruitingPhase 1/Phase 2
Study of new drug combo for advanced lung cancer
This study tests a new combination of cancer drugs (PF-08634404 with other anticancer agents) for people with advanced non-small cell lung cancer who have not yet received any treatment for their advanced disease. It aims to see if this combination can shrink tumors or slow cancer growth.
The Bronx, New YorkAges 18 years+ - NCT06568939RecruitingPhase 2
Study of telisotuzumab vedotin for non-squamous lung cancer
This trial tests a drug called telisotuzumab vedotin (ABBV-399) given through a vein to people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a high level of a protein called c-Met. The study aims to see how the drug affects the body and helps control the cancer.
The Bronx, New YorkAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
The Bronx, New YorkAges 18 years+ - NCT06865339RecruitingPhase 2
Radiation plus immunotherapy for advanced lung cancer
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
The Bronx, New YorkAges 18 years+ - NCT07169734RecruitingPhase 1/Phase 2
ALE.P03 for advanced CLDN1-positive solid tumors
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
Hackensack, New JerseyAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Lake Success, New YorkAges 18 years+ - NCT06452277RecruitingPhase 3
Testing sevabertinib for advanced HER2-mutated lung cancer
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
New Hyde Park, New YorkAges 18 years+ - NCT06899126RecruitingPhase 3
Study of a drug combo for first-line HER2-positive lung cancer
This trial tests a new combination of drugs (trastuzumab deruxtecan, pembrolizumab, and chemotherapy) as a first treatment for people with advanced non-small cell lung cancer that has high levels of the HER2 protein. The goal is to see if this combination works better than current options.
Westbury, New YorkAges 18 years+ - NCT06627647RecruitingPhase 3
Comparing two immunotherapy drugs for advanced lung cancer
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
Westbury, New YorkAges 18 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
White Plains, New YorkAges 18 years+ - NCT07222566RecruitingPhase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Nyack, New YorkAges 18 years+ - NCT06758401RecruitingPhase 3
Sigvotatug vedotin plus pembrolizumab for advanced lung cancer with high PD-L1
This trial tests a new combination of two study medicines for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see if adding sigvotatug vedotin to pembrolizumab works better than pembrolizumab alone.
Nyack, New YorkAges 18 years+ - NCT04317534RecruitingPhase 2
Pembrolizumab after lung cancer surgery versus observation
This trial tests whether pembrolizumab (an immunotherapy drug) given after complete surgery can lower the chance that early-stage lung cancer comes back. You’ll be compared to standard follow-up without extra treatment to see if the drug helps more people stay cancer-free.
New Brunswick, New JerseyAges 18 years+ - NCT07155187RecruitingPhase 2/Phase 3
Study of telisotuzumab adizutecan for EGFR-mutated lung cancer
This trial tests a new drug, telisotuzumab adizutecan (given through a vein), alone or with another targeted therapy, versus standard treatments for people with a specific type of advanced lung cancer that has an EGFR mutation and has gotten worse after previous treatment.
East Brunswick, New JerseyAges 18 years+ - NCT06357533RecruitingPhase 3
New drug combo for advanced lung cancer with high PD-L1
This trial tests a new two-drug combination (Dato-DXd and an immunotherapy called rilvegostomig) as the first treatment for people with advanced non-squamous lung cancer who have high PD-L1 levels. The goal is to see if this combination works better than current standard options.
Voorhees Township, New JerseyAges 18 years+ - NCT06236438RecruitingPhase 2/Phase 3
Livmoniplimab plus budigalimab and chemo for untreated lung cancer
This trial tests a new combination of two immune system drugs (livmoniplimab and budigalimab) plus standard chemotherapy compared to the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated yet. The goal is to see if the new combination works better at controlling the cancer.
Stony Brook, New YorkAges 18 years+ - NCT07388524RecruitingPhase 3
Testing atezolizumab after surgery for early stage lung cancer
This trial tests if the immunotherapy drug atezolizumab can prevent early stage non-small cell lung cancer from coming back after surgery. It is for people whose tumors have high levels of a protein called PD-L1 (50% or more) and do not have certain gene changes (EGFR or ALK).
Stony Brook, New YorkAges 18 years+
Hear when a new Non-squamous Non-small Cell Lung Cancer trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Where these studies are running near New York
Institutions with a site for the recruiting non-squamous non-small cell lung cancer studies listed above.
- Montefiore Medical Center · 4 studies
- Clinical Research Alliance · 3 studies
- Research Site · 3 studies
- Astera Cancer Care · 2 studies
- Hematology Oncology Associates of Rockland · 2 studies
- John Theurer Cancer Center at Hackensack University Medical Center · 2 studies
- Hackensack University Medical Center
- Hackensack University Medical Center at Paramus
What taking part in a non-squamous non-small cell lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there non-squamous non-small cell lung cancer clinical trials near New York?
- Yes. We're currently tracking 43 recruiting non-squamous non-small cell lung cancer studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a non-squamous non-small cell lung cancer study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a non-squamous non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New non-squamous non-small cell lung cancer studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.